Experts highlighted that robust pharmacopoeial frameworks are essential for maintaining the quality, safety and efficacy of medicines
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
API-first, DPI-driven DDRS platform aims to modernize drug and medical device regulation in India
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
A major push to sharpen the future of cancer treatment is underway
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
Subscribe To Our Newsletter & Stay Updated
